TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00364273
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo administered using DISKUS inhaler.
Study: NCT00641381
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/kg on day -2 prior to stem cell reinfusion
Study: NCT03514511
Drug: LEO 138559
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LEO 138559 is a compound in development at LEO Pharma A/S
Study: NCT03514511
Drug: LEO 138559 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEO 138559 placebo
Study: NCT02251548
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV alkylator chemotherapy agent
Study: NCT03555851
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmacogenomics of candidate genes and pharmacokinetic analyses of cyclophosphamide administered as part of a reduced intensity conditioning (RIC) regimen and as post-transplant GVHD prophylaxis will be examined.
Study: NCT01558869
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1200 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
Study: NCT03471039
Drug: PACAP27
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of PACAP27 over 20 minutes.
Study: NCT01230775
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Week 1:~1. x1 tablet/d of placebo will be administered in week 1.~   Week 2~   Placebo:~2. x1 tablet/d of placebo will be administered in week 2.~Week 3 - Week 4~Placebo:~In week 3 and week 4 the maximum dose is 4 tablets per day.~Placebo:~In order to guarantee blinding of subjects the number of placebo tablets to be taken by the subject will vary during maintenance period:~Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/
Study: NCT03869684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo manufactured to mimic MT-0814
Study: NCT02873520
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
Study: NCT00931346
Drug: FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: emtricitabine/tenofovir disoproxil fumarate
Study: NCT00931346
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00415142
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration (capsules)
Study: NCT01856764
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast formulation vehicle
Study: NCT01358071
Drug: Pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/m² iv every 4 weeks until confirmed evidence of disease progression
Study: NCT01358071
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m² iv every 3 weeks for a maximum of 8 cycles
Study: NCT04224545
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo started a day before surgery, 2, 3, 4, 5 days after surgery.
Study: NCT02905799
Drug: oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally : 2 caplets twice a day for one week, then 1 caplet twice a day, for a total duration of 6 months
Study: NCT04295109
Drug: the drug of intravenous patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: At present, opioids are most widely used in postoperative analgesia. This study aims to use different opioid receptor agonists---fentanyl, oxycodone and butorphanol for analgesia after laparoscopic hysterectomy.Compare the recovery of gastrointestinal function after operation.
Study: NCT00789568
Drug: sapropterin dihydrochloride
Normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 20 mg/kg and 100 mg/kg
Study: NCT00654446
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02656095
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be given IV heparin in order to release lipoprotein lipase from capillary endothelial cells. Blood will be drawn 10-15 minutes post-heparin administration and run through assay to determine lipoprotein lipase levels.
Study: NCT00654446
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02514473
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04029688
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered once daily on Days 1-5 of each 28-day cycle at 250 milligrams per meter squared of body surface area (mg/m\^2) as an intravenous (IV) infusion.
Study: NCT00142844
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04304547
Drug: CKD-828, D097, D337, CKD-348 T1, CKD-348 T2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject of sequence A takes IP in the following order:~1. Each tablet of CKD-828 and D097 and D337 be taken at once~2. CKD-348 T1 1 tablet~3. CKD-348 T2 1 tabet
Study: NCT04590326
Drug: REGN5668
Approvals — FDA: no, EMA: no, PMDA: no
Description: REGN5668 will be administered by once weekly intravenous (IV) infusion.
Study: NCT04304547
Drug: CKD-348 T1, CKD-348 T2, CKD-828, D097, D337,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject of sequence B takes IP in the following order:~1. CKD-348 T1 1 tablet~2. CKD-348 T2 1 tablet~3. Each tablet of CKD-828 and D097 and D337 be taken at once
Study: NCT03452111
Drug: Nestorone + Testosterone Combination Gel
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The combined gel is a transdermal treatment that will be applied daily for 52 weeks to a male subject's arms and shoulders. The formulation will be a hydro alcoholic gel. About 9 to 14% of the steroid (T or NES) in the gel applied is available to the body. The amount of gel to be applied each application will be approximately 5 mL in volume.
Study: NCT04304547
Drug: CKD-348 T2, CKD-348 T1, CKD-828, D097, D337
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject of sequence C takes IP in the following order:~1. CKD-348 T2 1 tablet~2. Each tablet of CKD-828 and D097 and D337 be taken at once~3. CKD-348 T1 1 tablet
Study: NCT03967977
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab placebo to match
Study: NCT04424511
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mixture will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml / kg child weight.
Study: NCT04424511
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml (20 mg) / kg child weight.
Study: NCT01851694
Drug: GIP
Normalized name: GIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject in this arm will receive GIP infusion and placebo during a GPA test.
Study: NCT03210272
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT04243616
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 g/m\^2, IV, Day 1 of Cycles 1-4 of ddAC (2-week cycle)
Study: NCT04243616
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 g/m\^2, IV, Day 1 of Cycles 1-4 of dose-dense Adriamycin (Doxorubicin) and Cyclophosphamide (ddAC) (2-week cycle)
Study: NCT00677053
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stages I, II \& III: TAK-442 placebo-matching capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
Study: NCT03157505
Drug: Purethal Birch immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purethal birch was administered as perennial therapy: 24 months
Study: NCT00609362
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: One encapsulated placebo pill a day for 14 weeks
Study: NCT00065130
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00256880
Drug: GW786034
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01332565
Drug: GSK1349572
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg tablet
Study: NCT02128360
Drug: Gonadotropins
Normalized name: GONADOTROPINS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01525901
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution will be administered for three months subcutaneously.
Study: NCT00195845
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00298168
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline administered IV as a single bolus infusion with 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
Study: NCT03573648
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: The endocrine therapy given will depend on menopausal status.~Premenopausal women will receive tamoxifen AND either Goserelin or Leuprolide:~* Tamoxifen (20mg) will be given orally daily x 4 cycles. (Other Names: Nolvadex)~* Goserelin (3.6mg) will be given subcutaneously (under the skin) on Day 1 of each cycle x 4 cycles. (Other Names: Zoladex)~* Leuprolide (3.75mg) will be given intramuscularly (in the buttock, thigh, or upper arm) on Day 1 of each cycle x 4 cycles. (Other Names: Leuprorelin, Lupron, Eligard)~Postmenopausal women will receive letrozole:~- Letrozole (2.5mg) will be given orally daily each cycle x 4 cycles. (Other Names: Femara)
Study: NCT02711579
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02711579
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00845481
Drug: Betnovat® ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application 6 days a week for 3 weeks
Study: NCT00845481
Drug: Daivobet® ointment vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application 6 days a week for 3 weeks
Study: NCT04595786
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline was prepared in a 50ml syringe for intravenous pump
Study: NCT00150644
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablet, oral Daily for 12 weeks
Study: NCT03232138
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive ingredients
Study: NCT01804634
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: preparative regimen
Study: NCT02914535
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered orally once daily
Study: NCT02656212
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill, taken orally, one pill/day in the morning
Study: NCT03250013
Drug: ADHD medications
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03742908
Drug: Cefazolin/clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local implant immersion and/or breast pocket irrigation
Study: NCT01995006
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen tablets (500mg): 500 mg BID during 7 days
Study: NCT00908583
Drug: plasmapheresis
Normalized name: HAEMO-PAK UNIT FOR PLASMAPHERESIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive plasmapheresis 1.5 x plasma volume prior to each Bortezomib dose. Plasma volume replacement will be per physician discretion.
Study: NCT00984568
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisolone 40 mg/day or 1 mg/kg/day depending upon participant response.
Study: NCT00984568
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AZA administered orally at a dose of 2.0-2.5 mg/kg/day.
Study: NCT01025492
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet po daily
Study: NCT01726452
Drug: 5 Flourouracil/ Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Flourouracil 200 mg/m2/day every day for 21 days OR Capecitabine 625 mg/m2 twice daily orally). The choice between administering 5 Flourouracil or Capecitabine is at the discretion of the investigator.
Study: NCT02643394
Drug: Oral Acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg oral acetaminophen + 400mg oral celecoxib given within one hour of incision
Study: NCT01726452
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m², day 1 of each cycle (i.e. every 14 days).
Study: NCT03422822
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For subjects whose dose was changed from 100 mg Abrocitinib to placebo, one tablet will be administered to be taken orally once daily for the remainder of the study.
Study: NCT02643394
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg oral celecoxib given within one hour of incision + 1000mg IV acetaminophen within one hour prior to anesthetic emergence.
Study: NCT02964507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered.
Study: NCT00891709
Drug: LEO 29102
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-in-man. Healthy volunteers
Study: NCT02362594
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution administered IV on Day 1 of each 21-day cycle
Study: NCT01582854
Drug: Actovegin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actovegin solution for infusion and Actovegin tablets
Study: NCT01582854
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actovegin placebo-matching solution for infusion and Actovegin placebo-matching tablets
Study: NCT02391805
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered PO placebo capsules matched to RO6864018, either QOD or QWk for 12 weeks of treatment.
Study: NCT02391805
Drug: RO6864018
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered RO6864018 as 200-mg PO capsules at a dose of 800 mg or 1200 mg, either QOD or QWk for 12 weeks of treatment.
Study: NCT03872778
Drug: [177Lu]-NeoB
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[177Lu\]-NeoB peptide receptor radionuclide therapy: 370 MBq/mL (10 mCi/mL), solution for infusion
Study: NCT03872778
Drug: [68Ga]-NeoB
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[68Ga\]-NeoB radioactive diagnostic agent: 50 µg, kit for radiopharmaceutical preparation
Study: NCT01225315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered orally twice daily
Study: NCT01858129
Drug: Experimental group: Budicort by Inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Budicort twice daily
Study: NCT01858129
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02684669
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator
Study: NCT04048278
Drug: Saline Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Saline a 1.0 - 1.5 mg/kg loading infusion for perioperative pain control
Study: NCT03992339
Drug: ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010, orally, twice weekly, each 4 week (28-day) a cycle.
Study: NCT00287235
Drug: Standard Medical Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01262352
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral use, twice daily every 12 hours (q12h)
Study: NCT02235727
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02036554
Drug: Mycophenolic acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
Study: NCT00035347
Drug: IV azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg once daily
Study: NCT00035347
Drug: oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 x 250 mg once daily
Study: NCT01721980
Drug: GLPG0974
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01721980
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01390220
Drug: USL261
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01390220
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00450658
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 800mg orally 3 times daily for 24 weeks
Study: NCT04167514
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin solution administered intravenously
Study: NCT04318041
Drug: Artrodar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacerein (Artrodar):~D1-D28 (1 month): Artrodar (50 mg) 1 x 1 with evening meal D29-end of study (23 months): Artrodar (50 mg) 1 x 2 with meal
Study: NCT01644370
Drug: HAART
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: as per Thai HIV Treatment guidelines
Study: NCT01141179
Drug: LEO 27847
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mL (0.1 mg) dose of oral solution
Study: NCT04063527
Drug: adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of paclitaxel and carboplatin
Study: NCT02261025
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75-100mg,per day
Study: NCT03989037
Drug: SIBP-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBP-01: injection; strength: 150mg; first dose 8mg/kg (intravenous infusion, not less than 90 minutes, on the 1st day of each cycle), then 6mg/kg once every 3 weeks, totaling 6 cycles
Study: NCT03669367
Drug: hydroxycloroquina
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral hydroxycloroquina 5 mg/Kg/day for 2 years (0-48 months)
Study: NCT01689740
Drug: Full Dose MDMA-assisted therapy (125 mg)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose of 125 mg midomafetamine HCl administered orally at the start of each of two psychotherapy sessions, possibly followed by a supplemental dose of 62.5 mg 1.5 to 2.5 hours later.
Study: NCT01689740
Drug: Open-Label Full Dose MDMA-assisted therapy (125 mg)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose of 125 mg midomafetamine HCl administered orally at the start of each of two psychotherapy sessions, possibly followed by a supplemental dose of 62.5 mg 1.5 to 2.5 hours later.
Study: NCT02956005
Drug: ENVARSUS®
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENVARSUS XR is a form of the anti-rejection drug, tacrolimus, for people who have had a kidney transplant
Study: NCT01440257
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules once daily
Study: NCT01440257
Drug: CCX140-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCX140-B capsules once daily (Group B)
Study: NCT01115582
Drug: Cholic acid
Normalized name: Cholic Acid
DrugBank: Cholic Acid (DB02659)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The IUPAC name for cholic acid is 3 alpha,7alpha,12 alpha-trihydroxy-5 beta-cholanoic acid. The international nonproprietary name (INN) is cholic acid.~Each patient will be given a box containing a 1 month supply of study drug. Each bottle will contain 90 capsules; each capsule will contain either 50 or 250 mg of manufactured cholic acid depending upon the child's weight. The study drug will be taken orally, in divided doses (as determined by the investigator), for a total daily dose of 10-15 mg/kg body weight. Parents of infants and young children who are unable to swallow the TBM cholic acid capsule will be instructed to sprinkle the contents of the capsule over 1-2 teaspoons of plain applesauce and feed it to the child.
Study: NCT04562766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg Caplet
Study: NCT03997266
Drug: Gentamycin
Normalized name: Gentamicin Sulfate 3 MG/1 ML Ophthalmic Solution [GENTAMYCIN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gentamycin
Study: NCT03997266
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous normal saline
Study: NCT02942576
Drug: VKA-Based Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosed at International Normalised Ratio (INR) levels, which is a test of how long it takes for blood to clot. Standard of Care treatment in Canada, Italy, Poland, Hungary, Czech Republic, United Kingdom (UK), Taiwan and Korea.
Study: NCT02942576
Drug: VKA-Based Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosed at INR levels. Standard of Care treatment in Germany, Belgium, and the Netherlands.
Study: NCT02942576
Drug: VKA-Based Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosed at INR levels. Standard of Care treatment in France.